کد مقاله | کد نشریه | سال انتشار | مقاله انگلیسی | نسخه تمام متن |
---|---|---|---|---|
5515205 | 1541833 | 2017 | 9 صفحه PDF | دانلود رایگان |
- CP-154,526 and DMP695 reduced separation-induced distress calls in guinea pig pups.
- Transgenic CRF-overexpressing mice emitted more distress calls than wild type mice.
- CP-154,526 reduced vocalizations similarly in CRF transgenic and wild type mouse pups.
- CRF1 receptor antagonists did not augment the effect of paroxetine on distress calls.
- GR antagonists had no effect on vocalization in guinea pig or CRF transgenic pups.
RationaleGiven the large number of patients that does not respond sufficiently to currently available treatment for anxiety disorders, there is a need for improved treatment.ObjectivesWe evaluated the anxiolytic effects of corticotropin releasing factor (CRF)1 receptor antagonists and glucocorticoid receptor (GR) antagonists in the separation-induced vocalization test in guinea pigs and transgenic mice with central CRF overexpression. Furthermore, we explored effects of these drugs when given in combination with a suboptimal dose of a selective serotonin re-uptake inhibitor (SSRI).MethodsIn guinea pig pups, the CRF1 receptor antagonists CP-154,526 and DMP695, and the GR antagonists mifepristone and Org34517 (all at 2.5, 10 and 40Â mg/kg intraperitoneally (IP)) were tested alone or in combination with 0.63Â mg/kg paroxetine IP. In CRF overexpressing mouse pups and wild type littermates, effects of CP-154,526 (10, 20 and 40Â mg/kg subcutaneously (SC)) and mifepristone (5, 15, 45Â mg/kg SC) were studied alone or in combination with 0.03Â mg/kg paroxetine SC.ResultsCRF1 but not GR antagonists reduced the number of calls relative to vehicle in guinea pigs and mice, independent of genotype. Treatment of CRF1 receptor or GR antagonists with paroxetine had no combined effect in guinea pigs, wild type or CRF overexpressing mice.ConclusionsCurrent results indicate robust anxiolytic properties of CRF1 receptor antagonists in guinea pigs and mice overexpressing CRF, and lack thereof of GR antagonists. Although no combined treatment effects were observed, it would be interesting to study combined treatment of CRF1 receptor antagonists with SSRIs following chronic drug administration.
Journal: Pharmacology Biochemistry and Behavior - Volume 154, March 2017, Pages 11-19